

9. (New) A method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered QID in an amount of 30 µg/dose.

10. (New) A method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered TID or QID in an amount of 60 µg/dose.

11. (New) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or an amylin agonist is administered in an amount of about 0.01 milligrams per day to about 5 milligrams per day.

12. (New) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered in an amount of about 0.05 milligrams per day to about 2 milligrams per day.

13. (New) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered in an amount of about 0.1 milligrams per day to about 1 milligram per day.

14. (New) A method of treating obesity in a human subject comprising administering to said subject a composition comprising a compound selected from the group consisting of amylin agonists, and pharmaceutically acceptable salts thereof.

15. (New) The method of claim 1, 2 or 3, wherein the weight of said human subject is lower following four weeks of treatment.